• Necroptosis-Induced Interferon Drives Protective Anti-Tumor

  2026-06-04

  This study demonstrates that RIPK3-driven necroptosis, independent of NF-κB-associated cytokine release, robustly stimulates type I interferon responses and elicits CD4+ T cell-mediated anti-tumor immunity. The findings clarify the distinct immunogenic roles of necroptotic cell death in cancer models and provide mechanistic insight for immunotherapy strategies.

• PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SL

  2026-06-04

  This study demonstrates that loss of PERK function primes colorectal cancer cells for ferroptosis by downregulating SLC7A11, a key cystine transporter. The findings elucidate the interplay between ER stress signaling and ferroptosis, offering new avenues for overcoming therapy resistance in cancer.

• Molnupiravir Blocks Lethal Bourbon Virus Infection in Mice

  2026-06-03

  This study demonstrates that molnupiravir, an orally available nucleoside analogue, robustly inhibits Bourbon virus (BRBV) replication and disease progression in a mouse model. The findings highlight both the antiviral potential of nucleoside analogues for tick-borne RNA viruses and the translational pathway for future therapeutic evaluation in humans.

• HyperScript™ Reverse Transcriptase: Enhanced cDNA Synthesis

  2026-06-03

  HyperScript™ Reverse Transcriptase streamlines the conversion of challenging or low-abundance RNA into high-quality cDNA, enabling robust qPCR and transcriptome profiling. Its engineered stability and specificity set new standards for RNA to cDNA workflows, especially where complex secondary structures impede traditional enzymes.

• HMGB1 as an Early Serum Biomarker for Diabetic Nephropathy

  2026-06-02

  Peng et al. utilized quantitative proteomics to identify HMGB1 as a promising serum biomarker for early detection and monitoring of diabetic nephropathy (DN). Their findings highlight the limitations of traditional diagnostic markers and offer a refined approach for noninvasive DN surveillance with potential translational impact.

• Iptacopan (LNP023): Precision Alternative Pathway Blockade i

  2026-06-02

  Explore how Iptacopan (LNP023) redefines alternative pathway C3bBb inhibition in translational research. This article delivers advanced protocol insights and critical analysis for complement activation studies, distinguishing itself from existing reviews.

• MDM1 Overexpression Enhances Apoptosis and Chemoradiotherapy

  2026-06-01

  This study identifies MDM1 as a key modulator of chemoradiotherapy sensitivity in colorectal cancer through upregulation of p53 and apoptosis pathways. The findings highlight MDM1’s role as a predictive biomarker and provide mechanistic insight with potential translational relevance for overcoming resistance in colorectal cancer treatment.

• MDM1 Overexpression Enhances Chemoradiotherapy Response in C

  2026-06-01

  The referenced study demonstrates that MDM1 overexpression increases p53 expression and apoptosis, leading to improved sensitivity of colorectal cancer (CRC) cells to chemoradiotherapy. These findings highlight MDM1 as both a functional biomarker and a potential therapeutic target for overcoming treatment resistance in CRC.

• Cyclic di-GMP as Antitoxin: Regulating Biofilm Persistence a

  2026-05-31

  Liao, Yan et al. (2024) reveal a novel toxin-antitoxin module in bacterial biofilms, where cyclic di-GMP acts as an antitoxin to regulate genome stability and antibiotic persistence. This discovery advances our understanding of biofilm resilience and offers new directions for targeting persistent infections.

• Z-VAD-FMK in Apoptosis Inhibition: Protocols & Advanced Use-

  2026-05-30

  Z-VAD-FMK stands out as a gold-standard pan-caspase inhibitor, enabling researchers to dissect apoptosis from emerging cell death pathways like ferroptosis. This guide details optimized workflows, advanced applications, and troubleshooting strategies—backed by recent breakthroughs and proven performance in diverse experimental models.

• Magnetic Bispecific Nano-Antibodies Enable In Vivo CAR-T-Mim

  2026-05-29

  This study introduces a magnetic bispecific nano-antibody platform (M-BiNanoAb) that enables the in vivo generation and magnetic guidance of CAR-T-mimicking cells for solid tumor therapy. The work addresses long-standing obstacles in solid tumor immunotherapy by enhancing T cell infiltration and cytotoxicity, opening new directions for next-generation cell-based cancer treatments.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Workflow & B

  2026-05-29

  APExBIO’s HyperScribe T7 High Yield Cy3 RNA Labeling Kit transforms fluorescent RNA probe synthesis, delivering robust labeling efficiency and workflow flexibility for demanding applications like in situ hybridization and Northern blotting. This guide details optimized protocols, troubleshooting, and how emerging mRNA delivery strategies inform next-generation probe design.

• Topotecan and Cisplatin in First-Line Small Cell Lung Cancer

  2026-05-28

  This article critically examines recent findings on the use of topotecan, alone and in combination with cisplatin and etoposide, as first-line therapy for small cell lung cancer (SCLC). The reviewed study highlights the efficacy, toxicity profiles, and ongoing challenges in optimizing treatment regimens, with practical implications for designing future cancer research protocols.

• Z-WEHD-FMK (A1924): Precision Caspase Inhibition for Reliabl

  2026-05-28

  This authoritative guide addresses real-world challenges in cell viability and inflammation research, demonstrating how Z-WEHD-FMK (SKU A1924) enables reproducible, quantitative control of caspase-1/4/5 activity. Integrating scenario-driven Q&A and evidence-backed optimization, it provides actionable strategies for biomedical researchers seeking reliable inhibition of inflammatory caspases, with practical links to protocols and vendor selection.

• Cediranib (AZD2171): Optimizing VEGFR Assays in Cancer Resea

  2026-05-27

  Cediranib (AZD2171) empowers researchers to dissect angiogenesis and tumor signaling with high precision, thanks to its potent and selective VEGFR inhibition. This article outlines advanced workflows, practical troubleshooting, and actionable protocol parameters that elevate reproducibility and insight in cancer biology studies.

11541 records 1/770 page Next 12345 下5页 Last page